A simple blood test drawn from a pregnant woman may help determine whether her baby is at risk for fetal and neonatal alloimmune thrombocytopenia (FNAITFetal and neonatal alloimmune thrombocytopenia A rare condition in which a mother’s immune system attacks fetal platelets, leading to dangerously low platelet levels before and/or after birth.), a rare but potentially serious condition, according to a review published in Transfusion Medicine Reviews.
FNAIT occurs when a mother’s immune system makes antibodies that attack her baby’s platelets — the tiny cell fragments that help blood clot. This can cause the baby’s platelet countPlatelet count A measure of how many platelets are in the blood. FNAIT is characterized by severely reduced counts in a fetus or newborn. to fall to dangerous levels and, in severe cases, bleeding in the brain.
Even though the condition can develop unexpectedly, even during a first pregnancy, it is not part of routine prenatal screening and often goes undetected until after birth. Identifying a baby’s platelet antigen type early would give doctors time to plan treatments that can lower these risks.
Learn more about FNAIT treatment and care
The review examined six European studies that used noninvasive testing to determine a fetus’s platelet antigen type. These tests analyze cell-free fetal DNA — small fragments of the baby’s genetic material that circulate in the mother’s blood. This approach avoids the downsides of invasive procedures such as amniocentesis, which involves inserting a needle into the womb and carries, even though small, a risk of complications such as miscarriage or infection.
Across the studies, the blood tests closely agreed with the results of established invasive diagnostic methods.
Accuracy was strongest for HPAHuman platelet antigen Proteins found on the surface of platelets. Incompatibility between maternal and fetal human platelet antigens can trigger FNAIT.-1a, the human platelet antigenHuman platelet antigen Proteins found on the surface of platelets. Incompatibility between maternal and fetal human platelet antigens can trigger FNAIT. responsible for most FNAIT cases in people of European descent.
The studies tested several laboratory techniques. Traditional methods based on polymerase chain reaction (PCR), a technique that makes many copies of a DNA segment so it can be detected, reliably identified HPA-1a and can run in routine laboratories from about 12 to 15 weeks of pregnancy. These methods are dependable for detecting one antigen at a time.
More advanced methods, including droplet digital PCR and next-generation sequencing, could screen for several antigen types at once, including rarer ones, and worked as early as 9 to 10 weeks, though they require specialized laboratories.
The authors concluded that the differences between methods “are defined less by diagnostic accuracy than by technical characteristics and practical implementation.” They suggested that future research should focus less on small gains in accuracy and more on standardizing these tests and integrating them into routine prenatal care.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
